CMND — Clearmind Medicine Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1892500 ·
Last close
$2.03
Market Cap
$3.02M
52W High
$15.20
52W Low
$2.00
ADV30
3,623,398
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -1,571,209 | -2,047,653 | 14,523,512 | 11,415,719 | 3,032,771 |
| Jan 2026 | 0 | — | -3,659,915 | -3,854,583 | 11,143,419 | 9,257,766 | 2,905,011 |
| Oct 2025 | 0 | — | -1,456,258 | -687,842 | 6,083,052 | 3,923,058 | 4,890,456 |
| Jul 2025 | 0 | — | -1,407,764 | -1,313,592 | 3,969,546 | 3,495,338 | 2,903,878 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,554,012
Investing CF
$-611,479
Financing CF
$9,634,911
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-29.27
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-31,734,307
Inventory
—
Receivables
$437,642
ST Investments
$1,089,438
EBIT TTM
$-7,141,525
Pretax Income TTM
$-6,604,875
Interest Exp TTM
$15,776
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Oct 2025 | 0 | -5,667,177 | -3,856,983 | 6,083,052 | 4,890,456 | — | -4,734,498 |
| Oct 2024 | 0 | -5,744,925 | -5,254,678 | 7,255,414 | 4,147,862 | — | -4,858,659 |
| Oct 2023 | 0 | -6,303,434 | -8,620,837 | 5,953,288 | 4,969,816 | — | -6,301,472 |
| Oct 2022 | 0 | -6,251,431 | -6,894,868 | 826,415 | 1,932,413 | — | -3,724,494 |
| Oct 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CASIF | CASI Pharmaceuticals, Inc. | $2.98M | $0.15 | — |
| GRI | GRI Bio, Inc. | $3.08M | $1.74 | — |
| DCOY | Decoy Therapeutics Inc. | $3.14M | $5.91 | — |
| BIXT | BIOXYTRAN, INC | $2.87M | $0.03 | — |
| RLFTF | MindMaze Therapeutics Holding SA | $3.21M | $0.25 | — |
News headlines (Yahoo Finance, 1h cache)
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
2026-07-10 12:32 · Yahoo
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
2026-07-07 11:42 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-07-06 19:53 · Yahoo
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
2026-06-29 11:55 · Yahoo
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
2026-06-22 12:07 · Yahoo
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
2026-06-18 11:55 · Yahoo
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
2026-06-16 11:32 · Yahoo
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
2026-06-05 11:32 · Yahoo
Why Did CMND Stock Jump 40% Today?
2026-05-29 15:04 · Yahoo
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
2026-05-29 12:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.